Surgery Partners (SGRY) Reports Earnings Tomorrow: What To Expect

Healthcare company Surgery Partners (NASDAQ:SGRY) will be reporting results this Tuesday before market open. Here’s what to expect.

Surgery Partners met analysts’ revenue expectations last quarter, reporting revenues of $776 million, up 8.2% year on year. It was a slower quarter for the company, with a significant miss of analysts’ EPS estimates and full-year revenue guidance meeting analysts’ expectations.

Is Surgery Partners a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Surgery Partners’s revenue to grow 7.1% year on year to $816.1 million, slowing from the 14.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.14 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Surgery Partners has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Surgery Partners’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts’ expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health’s stock price was unchanged.

Read our full analysis of Select Medical’s results here and CVS Health’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Surgery Partners is down 3.4% during the same time and is heading into earnings with an average analyst price target of $31.08 (compared to the current share price of $21.28).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.